Biotech Co.*
(Country; Symbol)

Pharma Co.
(Country)

Type/Product Area

Terms/Details (Date)


20/20 Gene-
Systems Inc.*

Novartis AG (Switzerland)

Technology access agreement in which Novartis gains access to 20/20's Protein Function Identification Layered Membranes to identify protein expression and activation patterns in tumor samples

Novartis will provide funding and tissue samples (10/9)

4SC AG*
(Germany)

Schering AG
(Germany)

Research collaboration to identify molecules that bind to a specific undisclosed target provided by Schering to serve as the basis for drug discovery

4SC will use its 4SCan high-throughput screening technology to evaluate a pool of 3.3M small organic molecules for their binding efficacy to the given target; 4SC will receive undisclosed research funding and milestone payments (10/8)

Aegera
Therapeutics*
(Canada)

Wyeth

Nonexclusive license granting Wyeth access to Aegera's adenovirus technology

The license also grants Wyeth the right to practice the adenovirus transfection method; the agreement calls for an undisclosed up-front payment and annual main- tenance fees to Aegera (10/1)

Affymetrix Inc.
(AFFX)

Schering-Plough Research Institute

Agreement under whichSPRI gains access to Affymetrix's standard and custom GeneChip arrays, instrumentation and software

They will be used to monitor gene expression for use in biopharmaceutical research and development activities (10/22)

Amersham Biosciences (unit of Amersham plc;
NYSE:AHM)

Pharmacia Corp. and Novartis Pharma AG (Switzerland)

Licensing agreements enablingthe companies to use Amersham's green fluorescent protein vectors in their drug discovery research

The license includes access to intellectual property associated with folding and red-shifted mutations (9/19)

Amylin
Pharmaceuticals

Inc.
(AMLN)

Eli Lilly and Co.

Global agreement to collaborate on the development and commercialization of Amylin's late-stage Type II diabetes candidate, AC2993

The deal could mean more than $435M for the biotech company, including up-front, equity and milestone payments (9/20)

Arena
Pharmaceuticals

Inc.
(ARNA)

Merck & Co.
Inc.

Collaboration to validate three orphan GPCRs of interest

Merck paid $4M up front, and will pay $10M more in milestone payments in the next 12 months; Arena also is entitled to royalties; Arena will deploy its receptor technologies known as CART and Melanophore (10/17)

Astex
Technology
Ltd.*

Mitsubishi Pharma
Corp. (Japan)

Collaboration in the area of metabolic disorders

Collaboration will identify lead compounds against a protein target; they will then be extended to other targets; Astex will apply its high-throughput X-ray crystallography and Pyramid approach to fragment-based drug discovery against the target (10/21)

Atrix
Laboratories

Inc.
(ATRX)

Sanofi-
Synthelabo
(France)

Licensing agreement for an extended-release Eligard

Atrix licensed the formulation from Sanofi; Atrix will receive research and development reimbrusement and payments for regulatory and sales milestones, as well as royalties on sales; it also will manufacture Eligard (10/1)

Biolex Inc.*

Bayer Corp.

Research collaboration anddevelopment option agreement to examine the feasibility of producing human plasminogen and an additionalundisclosed human therapeutic protein

The companies will use Biolex's patented Lemna System (10/3)

Biosynexus*

GlaxoSmithKline Biologicals (UK)

Agreement for the development of vaccines and antibodies designed to fight infections caused by staphylococcal bacteria

Biosynexus' product, BSYX-A110, a monoclonal antibody to prevent staphylococcal infections, is included in the agreement; each company will share the costs of developing BSYX-A110; the deal is worth up to $120M through access fees, equity investments and milestone payments to Biosynexus (10/2)

Biovitrum AB*
(Sweden)

GlaxoSmithKline
plc (UK)

Agreement to develop Biovitrum's 5-HT2C receptor agonists to treat obesity

The deal is worth a potential $150M for Biovitrum; it could mean more money if products are developed in other indications; GlaxoSmithKline will pay Biovitrum an up-front fee and milestone payments (10/23)

Cambridge
Antibody
Technology
plc
(UK; CATG;
LSE:CAT)

Chugai Pharmaceutical
Co. Ltd. (Japan)

Agreement to license CAT's antibody phage-display libraries for the discovery, development and commercialization of human monoclonal antibodies

CAT will receive license fees from Chugai to use the antibody libraries for reagent generation and target validation; Chugai will receive exclusive therapeutic antibody product options and CAT will receive fees, clinical milestones and royalty payments on product sales (9/30)

Celera
Diagnostics

(joint venture between Applied Biosystems Group, NYSE:ABI, and Celera Genomics Group, NYSE:CRA)

Bristol-Myers
Squibb Co.

Collaboration to study genes that may be useful in the diagnosis and treatment of cardiovascular disease and diabetes

BMS will provide clinical samples and data to Celera, and it will receive exclusive rights to develop and market resulting drugs; Celera will retain exclusive rights to develop and market diagnostic products (10/7)

Celera
Genomics
Group
(NYSE:
CRA)

Bayer AG
(Germany)

Agreement in which Celera acquired a collection of early compounds from Bayer

Celera inherited the agreement when it acquired Axys Pharmaceuticals Inc. in 2001; the new deal gives Celera an entire set of compounds and intellectual property, and the rights to the compounds in all fields (10/8)

Cellular
Genomics Inc.*

Serono SA (Switzerland)

Collaboration for CellularGenomics to apply its chemical genetics technologies to four target kinases selected by Serono

Cellular Genomics will receive up-front payments and milestones over two years; the kinases are important in small-molecule drug discovery programs for autoimmune and inflammatory diseases (10/9)

Cerep SA*
(France)

F. Hoffmann-La Roche Ltd. (Switzerland)

Research agreement providing for Roche to have access to Cerep's database, BioPrint, and for Cerep to use its BioPrint informatics tools on behalf of Roche

Cerep will profile Roche compounds in a panel of in vitro biological assays (10/9**)

ChemCodes
Inc.*

Hoffmann-La Roche Inc.

Research agreement under which ChemCodes will use its chemistry platform todiscover and optimize synthetic reactions to produce lead compounds for a Roche target

Financial terms were not disclosed (10/15)

DeCode
genetics Inc.
(Iceland; DCGN)

Merck & Co.
Inc.

Agreement to develop a treatment for obesity

DeCode will receive research funding, technology access and license fees, and milestone and royalty payments on successfully marketed alliance drugs; the deal is worth more than $90M for DeCode (9/27)

Encelle Inc.*

Smith & Nephew
plc (UK)

Agreement to conduct the next phase of clinical trials of Encelle's first product, E-Matrix, for use in treating chronic wounds

Smith & Nephew will fund the trial and gain exclusive licensing rights to further develop and commercialize E-Matrix for skin wounds in humans (9/23)

Endovasc Ltd.
Inc.
(OTC
BB:ENVC)

NOF Corp.
(Japan)

Three-year license agreement containing automatic renewals in which NOF will represent Endovasc in Japan, Taiwan, Korea, China, Indonesia, Singapore, Malaysia, Philippines, Thailand, Vietnam and India

The parties also will collaborate on re- search and development by using NOF's lipid drug delivery systems to develop new products (10/9)

GeneData Inc.*

Wyeth

Licensing agreement to use GeneData's GeneData Phylosopher, its system for comparative functional genomics

Wyeth will use the system to analyze the genomes of pharmaceutically relevant pathogens by comparing them with all of the currently available and completely sequenced genomes from microbial and higher organisms (10/16)

Hydra
Biosciences

Inc.*

Abbott
Laboratories

Collaboration to continue animal studies to validate a therapy for proliferative vascular disease, and to focus on a small-molecule drug discovery program in an undisclosed disease area

The collaboration will provide multiyear funding for Hydra, including up-front payments, as well as potential milestone and royalty payments (10/9)

Igeneon AG*
(Austria)

Novartis AG
(Switzerland)

Licensing agreement for Novartis' IGN301 vaccine against epithelial cancers

Igeneon gains exclusive worldwide rights for clinical development and exploitation of the vaccine; Novartis gains an up-front fee, and could receive milestone payments and licensing fees on future sales (10/2)

Illumina Inc.
(ILMN)

GlaxoSmithKline
plc (UK)

Genotyping services agreement to develop a set of single nucleotide polymor phism markers into validated SNP assays

Illumina will develop the assays into a whole-genome linkage disequilibrium-mapping product (9/19)

Insmed Inc.
(INSM)

Pharmacia
Corp.

Exclusive licensing agreementgiving Insmed access to Pharmacia's portfolio of regulatory filings pertaining to insulin-like growth factor-1 to treat growth hormone insensitivity

Insmed plans to use the information to expedite the development and approval of SomatoKine (10/7)

Kosan
Biosciences

Inc.
(KOSN)

F. Hoffmann-
La Roche Ltd. (Switzerland)

Agreement partnering the early stage cancer product, KOS-862

Roche will have worldwide exclusive rights to KOS-862, although Kosan retains co-development and co-promotion rights in the U.S.; total committed funding and all milestones could reach as high as $220M (9/23)

Matritech Inc.
(NMPS)

Mitsubishi
Kagaku Medical
Inc. (Japan)

Agreement in which Matri- tech will complete the development of the NMP66 breast cancer test

Matritech will use Mitsubishi's input and conduct an initial validation study using specimens from women in Japan provided by Mitsubishi (10/11)

Mologen AG*
(Germany)

Undisclosed U.S. pharmaceutical company

Agreement for a feasibility study on a veterinary vaccine based on Mologen's MIDGE vector technology

Mologen believes the vector is suitable for delivering vaccines in both humans and animals (9/18**)

Neose
Technologies

Inc.
(NTEC)

Novo Nordisk
A/S (Denmark)

Research and development collaboration for the use of Neose's GlycoAdvance technology to make clinically significant improvements to a Novo Nordisk therapeutic protein

Financial terms were not disclosed (10/2)

NicOx SA
(France; Nouveau Marche:NICOX)

AstraZeneca
plc (UK)

Agreement giving Astra-Zeneca rights to develop and commercialize AZD 3582 and certain other COX-inhibiting nitric oxide-donators in Japan

NicOx will receive milestone payments totaling up to €22M (US$21.5M); NicOx also will receive an up-front payment and royalties of 12% on net sales of compounds concerned in Japan (9/30)

Norak
Biosciences
Inc.*

F. Hoffmann-
La Roche Ltd. (Switzerland)

Nonexclusive agreement to use Norak's Transfluor technology for G protein-coupled receptor drug discovery

Norak will provide its Transfluor cell lines expressing GPCR targets of interest to Roche; Norak also will sublicense a green fluorescent protein to Roche for use with Transfluor; Norak will receive up-front cash, assay development fees and could receive milestone payments (10/1)

Novactyl Inc.*

Upsher-Smith Laboratories
Inc.

Worldwide exclusive licensing agreement for PCL-016 and FSR-488 to treat cold sores and genital herpes

Novactyl will receive an up-front licensing fee, reimbursement for certain expenses, additional milestone payments and royal- ties; Upsher-Smith gains exclusive development and marketing rights on a worldwide basis for both compounds (10/1)

Perlegen
Sciences Inc.*

GlaxoSmithKline
plc (UK)

Collaboration to use whole-genome single nucleotide polymorphism scanning to identify genetic markers of drug response

The goal is to identify in a limited number of patients a pattern of markers that may be associated with a pharmacogenomic response (9/18)

Pharmacopeia
Inc.
(PCOP)

Kowa Co. Ltd.
(Japan)

Collaboration focused on inflammation

Pharmacopeia will provide its small- molecule discovery knowledge to identify leads against a Kowa target; Pharmacopeia will receive funding and could receive payments for milestones and royalties on approved drugs (10/23)

Pharmagene
plc
(UK; LSE:
PGN) (Germany)

Boehringer
Ingelheim
Pharma KG

Contract agreement giving Boehringer access to Pharmagene's Phase ZERO compound validation service

Pharmagene will evaluate a number of ringer's compounds in human cerebrovascular tissues (9/25**)

Pharmagenesis
Inc.*

Fujisawa Pharmaceutical
Co.

Research collaboration related to immunosuppressants based on Chinese herbal remedies being developed

The immunosuppressants are triptolide derivatives; Fujisawa has the option for the next year to make the decision to acquire exclusive, worldwide development and marketing rights to the compounds (9/24)

Pharsight Corp.
(PHST)

Sanofi-
Synthelabo
Recherche
(France)

Agreement in which Pharsight will implement the Pharsight Knowledgebase Server and upgrade related modeling software in its drug development efforts

Financial details were not disclosed (9/26)

Sequenom Inc.
(SQNM)

GlaxoSmithKline
plc (UK)

Agreement in which Sequenom sold two additional MassArray systems to GlaxoSmithKline

The sales follow an initial MassArray system purchase by GSK earlier this year (10/17)

SIGA
Technologies
Inc.
(SIGA)

TransTech
Pharma Inc.

Drug discovery collaboration using TransTech's TTP Translational Technology and SIGA's biological targets to seek small-molecule therapeutics to treat infectious diseases and neutralization of potential biowarfare agents

Companies will focus on discovering classes of anti-infectives to treat infectious diseases; they will share costs and any generated revenues (10/3)

Symyx Technologies
Inc.
(SMMX)

Kurt J. Lesker
Co.

Worldwide, nonexclusive license agreement for selected Symyx patents and technology that may enhance the performance and capabilities of KJLC's CMS-A and CMS-18 thin-film deposition tools

KJLC will develop, manufacture and distribute the instruments worldwide, with Symyx receiving royalty payments on product sales (9/19)

Variagenics
Inc.
(VGNX)

Strida Pharma
Inc. (Canada)

Option agreement for a worldwide license to certain of Variagenics' MTHFR (methylenetetrahydrofolate reductase) patent rights

Variagenics granted Strida the option for worldwide exclusive rights to commercialize therapeutic inhibitors of the MTHFR gene; terms include an up-front fee and may lead to milestone payments and royalties on sales of any compounds that are developed using the technology (10/16)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board